Episode 442: The History of ARPI Development in Prostate Cancer
Michael Morris from MSKCC joins us for an in-depth review of ARPI development across the spectrum of prostate caner
--------
51:12
--------
51:12
Episode 466: #UromigosLive 2025 - Novel Therapy in mRCC
Brian and Tom tag team moderate this session which covers combination data, VEGF/PD1 bispecifics, microbiome approaches, cellular therapy and enrichment strategies.
--------
53:03
--------
53:03
Episode 465: #UromigosLive 2025 - Adjuvant Therapy in RCC
Tom leads the panel discussion about this evolving space including the RAMPART data and the press release about pembro/belzu.
--------
44:49
--------
44:49
Episode 464: #UromigosLive 2025 - The Evolving Landscape of mHSPC
Brian moderates a panel of Chris Sweeney, Tanya Dorff, Mike Morris, Neeraj Aggarwal and Chuck Ryan as they discus and debate the mHSPC space with many treatment options.
--------
50:04
--------
50:04
Episode 459: #UromigosLive 2025 - Radioligands in Prostate Cancer
Brian leads a discussion of Rana McCay, Chris Sweeney and Michael Morris on the PSMAddition data and the landscape of radioligands in prostate cancer.
Broadcasting the latest developments in GU cancer
Hosted by Brian Rini and Tom Powles
Brian Rini MD is a Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center
Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London
México